Nordic Nanovector - Fundamentale forhold 2019 (NANO)

[Krieghoff]

Er jo open lable og de gjentar at data kommer i H219.

[Fornybar]

Up to 24 patients are planned to
be enrolled

Hvis de har kjørt doseeskalering til nå med 3+3+3 pasienter så ser jeg ikke på det som særlig urimelig at de kan si seg fornøyde med f.eks 9 pasienter med 20/100 den 30 juni.

[JustinBibel]

Stusser dog litt, for var det ikke guidet å ha siste pasient i 37-05 behandlet i løpet av 1h?

Jo, det stemmer - og det henger på greip med det de skriver i børsmeldingen.

Preliminary results are expected in the second half of 2019.

Dette går som tidligere beskrevet: We Are On Track.

[frogjo]

Mr Bravo var ivrig med å trekke frem DLBCL
da han kom i sjefsstolen…han hadde nok gode grunner…de sitter jo med resultater fra de første cohortene…dette lukter d fugl av

[kanon]

Interessant at de kjører kun 20/100.

Dette er jo en indikasjon med mange flere pasienter, så det bør være mulig å rekruttere fortere.

Når kan vi forvente safety ok archer?

[sparkonge]

Virker ikke som alle har studieoppsettet for Lymrit 37-05 (Betalutin for DLBCL) klart for seg:

[Savepig]

Jeg liker at de endte opp med 20/100, jo flere pasienter enn får testet den doseringen på, jo bedre blir totalbildet av data selskaper sitter på.

[Oilimp]

Jeg liker at de endte opp med 20/100, jo flere pasienter enn får testet den doseringen på, jo bedre blir totalbildet av data selskaper sitter på.

Når kan vi forvente noe data fra denne studien, tror folket?
Og for Archer-1?

[kanon]

Fra pressemeldingen: Preliminary results are expected in the second half of 2019.

Archer-1 safety burde ta ca like lang tid som DLBCL, hvor lang tid tok den?

[Oilimp]

Preliminary results are expected in the second half of 2019.

Takker, det jeg mente å huske.

[Savepig]

Lymphomation.org (Lymphomation)

[TekBot]

25/04-2019 16:18:45: (NANO, NANOO.ST) Nordic Nanovector ASA: Annual General Meeting held

Oslo, Norway, 25 April 2019

The Annual General Meeting of Nordic Nanovector ASA (the “Company”) (OSE: NANO) was held today on 25 April 2019 in Oslo, Norway.
…

Vis børsmeldingen

All proposals were resolved by the Annual General Meeting as presented in the notice convening the general meeting distributed on 4 April 2019.

The complete minutes of the Annual General Meeting are attached to this release, and are available on www.nordicnanovector.com.

For further information, please contact:

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: [email protected]

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37 -targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act.

 

http://www.netfonds.no/quotes/release.php?id=20190425.Cision.20190425:BIT:5477:0

[anon80503862]

Litt interessant at 18% stemte mot forhøyelse til emisjonsfullmakt til 20%. Tydeligvis det ene store punktet det var uenighet om.

[Make_me_smile]

Det var ca 25% av aksjene som stemte. Det hensyntatt kan en vel kanskje tro at det var ca 4,5% som stemte mot en evt forhøyning av aksjekapital på 20%.

Det kan se ut til at Healtcap ikke har har stemt, mulig det har noe med emisjonsaksjene å gjøre.

[TekBot]

29/04-2019 08:00:09: (NANO) Nordic Nanovector appoints Fredrik Haavind as Head of Legal and Compliance

Oslo, Norway, 29 April 2019

Nordic Nanovector ASA (OSE: NANO) announces the appointment of Fredrik Haavind
…

Vis børsmeldingen

as the newly established Head of Legal and Compliance. Mr Haavind has 16 years
of broad legal and compliance experience in Norwegian and International
businesses, including international contracts law, governance and compliance,
M&A, corporate and securities laws and regulations, with experience from in
-house legal departments, law firms and the courts. He joins Nordic Nanovector
from Fugro N.V., a global provider of geo-intelligence listed on Euronext,
Amsterdam, where he acted as Head of Legal Europe.

Mr Haavind has a law degree from the University of Oslo, a degree in Business
Administration from the Norwegian School of Management and an LL.M. - Master in
International Business Law from King’s College, London.

Tone Kvåle, Nordic Nanovector CFO, said: “We welcome Fredrik to the team and
value the experience and capabilities he brings as our legal and compliance
requirements increase in parallel with the development of the business.”

Fredrik Haavind added: “I am very pleased to join Nordic Nanovector. The company
is at an important juncture as it increases its pre-commercial activities and I
am looking forward to supporting its further development.”

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: [email protected]

International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: [email protected]

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37
-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s
lymphoma (NHL). NHL is an indication with substantial unmet medical need,
representing a growing market forecast to be worth nearly USD 29 billion by
2026. Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com

Forward-looking statements

This press release contains certain forward-looking statements. These statements
are based on management’s current expectations and are subject to uncertainty
and changes in circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector’s business, financial condition and results
of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”,
“estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”,
“should”, “projects”, “targets”, “will”, “would” or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector’s
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector’s product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector’s potential market and
industry, Nordic Nanovector’s freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Section 5-12 of
the Securities Trading Act.

http://www.netfonds.no/quotes/release.php?id=20190429.OBI.20190429S16

[Savepig]

Ansettelse helt på det jevne, ingen grunn til å tro at han mangler kvalifikasjoner, men selvsagt hadde vi ønsket noen som hadde tilsvarende erfaring fra Pharma eller biotech

[Make_me_smile]

Mulig han har det i blodet - tipper han er sin fars sønn

https://haavind.no/en/expertise/sector/healthcare-lifescience/

[Savepig]

Er denne studien relevant for Betalutin å skjele til?

Nå virker ikke konklusjoen alarmistisk i og for seg da:

CONCLUSION:

The general pattern of the time- and dose-dependent induction and disappearance of radiation-induced foci (RIF) during 177Lu-PSMA therapy is similar to that of other radionuclide therapies.

DNA damage in blood leucocytes of prostate cancer patients during therapy with 177Lu-PSMA.

[pdx]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @Savepig (589 likes)

Ble akkurat postet et papir på twitter som jeg ikke har sett før, hvor Dr Zinsani er en av forfatterene.

2. @TyrionIV (376 likes)

Har lagd en liten oppsummering av salget til Lutathera og sammenligningen med Betalutin som jeg hadde tidligere i uka over flere innlegg på småprat-tråden siden dette gav meg veldig gode vibber ift de nærmeste 2-3 årene.

3. @studenten86 (346 likes)

Nordic Nanovector Aksjonærlister og Shortaktører (NANO)

Resten av topp 10:

4. @anon21766851 (275 likes)

5. @vegar_beider (178 likes)

6. @Zuba (155 likes)

7. @InVivo (144 likes)

8. @Merlin (134 likes)

9. @Fornybar (134 likes)

10. @Oilimp (133 likes)

Gratulerer!